FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

The FDA granted full approval to tisotumab vedotin for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Related Keywords

,Tisotumab Vedotin ,Fda ,Cervical Cancer ,Full Approval ,Fda Approval ,